EPM1
MCID: MYC080
MIFTS: 52

Myoclonic Epilepsy of Unverricht and Lundborg (EPM1)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myoclonic Epilepsy of Unverricht and Lundborg

MalaCards integrated aliases for Myoclonic Epilepsy of Unverricht and Lundborg:

Name: Myoclonic Epilepsy of Unverricht and Lundborg 56 73
Progressive Myoclonic Epilepsy 56 52 58 36 29 6
Epilepsy, Progressive Myoclonic 1a 56 29 13 6
Familial Progressive Myoclonic Epilepsy 52 71
Baltic Myoclonic Epilepsy 56 73
Epm1a 56 73
Epm1 56 73
Uld 56 73
Pme 56 58
Progressive Myoclonic Epilepsy Unverricht-Lundborg Type 73
Epilepsy, Progressive Myoclonic, 1a; Epm1a 56
Epilepsy, Myoclonic, Progressive, Type 1a 39
Epilepsy, Progressive Myoclonic, 1; Epm1 56
Epilepsy, Progressive Myoclonic, 1a 56
Progressive Myoclonic Epilepsy; Pme 56
Epilepsy, Progressive Myoclonic, 1 56
Epilepsy, Progressive Myoclonic 1 73
Progressive Myoclonic Epilepsy 1a 73
Myoclonic Epilepsies, Progressive 71
Progressive Myoclonic Epilepsy 1 73
Myoclonic Epilepsy, Progressive 56
Progressive Myoclonus Epilepsy 58
Epilepsy Progressive Myoclonic 74
Unverricht-Lundborg Syndrome 71

Characteristics:

Orphanet epidemiological data:

58
progressive myoclonic epilepsy
Age of onset: Adolescent,Childhood,Infancy,Neonatal;

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
onset 6-13 years
three stages of disease progression - stage 1 (subclinical), stage 2 (early myoclonic), stage 3 (disabling myoclonic)
incidence of 1 in 20,000 live births
high frequency in finnish population


HPO:

31
myoclonic epilepsy, progressive:
Inheritance x-linked inheritance

myoclonic epilepsy of unverricht and lundborg:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

OMIM Phenotypic Series 56 PS254800
KEGG 36 H00810
MeSH 43 D020191
MESH via Orphanet 44 D020191
UMLS via Orphanet 72 C0751778
Orphanet 58 ORPHA98261
UMLS 71 C0751777 C0751778 C0751785

Summaries for Myoclonic Epilepsy of Unverricht and Lundborg

KEGG : 36 Progressive myoclonic epilepsy (EPM) is a syndrome complex characterized by progressive myoclonus, cognitive impairment, ataxia, and other neurologic deficits. PME is a disease that afflicts previously normal children with ever-worsening and soon-intractable myoclonus and epilepsy, usually associated with neurodegeneration, and eventual dementia and early death. PME include Lafora disease, Unverricht-Lundborg disease, the neuronal ceroid lipofuscinoses, type I sialidosis (cherry-red spot myoclonus), Dentatorubro-pallidoluysian atrophy (DRPLA), and type III Gaucher disease. Almost all the autosomal recessively inherited PMEs are lysosomal diseases, with the exception of Lafora disease in which neither the accumulating material nor the gene products are in lysosomes. PME also occurs in various forms of mitochondrial encephalomyopathies, especially in myoclonic epilepsy with ragged-red fibers (MERRF).

MalaCards based summary : Myoclonic Epilepsy of Unverricht and Lundborg, also known as progressive myoclonic epilepsy, is related to progressive myoclonus epilepsy 10 and progressive myoclonus epilepsy 1a, and has symptoms including ataxia and myoclonus. An important gene associated with Myoclonic Epilepsy of Unverricht and Lundborg is CSTB (Cystatin B). The drugs Brivaracetam and Zonisamide have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and bone, and related phenotypes are ataxia and myoclonus

NIH Rare Diseases : 52 Progressive myoclonus epilepsy (PME) refers to a group of inherited conditions involving the central nervous system and representing more than a dozen different diseases. These diseases share certain features, including a worsening of symptoms over time and the presence of both muscle contractions (myoclonus ) and seizures (epilepsy ). PME is different from myoclonic epilepsy. Other features include dementia , dystonia , and trouble walking or speaking. These rare disorders often get worse over time and sometimes are fatal. Many of these PME diseases begin in childhood or adolescence.

OMIM : 56 Myoclonic epilepsy of Unverricht and Lundborg is an autosomal recessive disorder characterized by onset of neurodegeneration between 6 and 13 years of age. Although it is considered a progressive myoclonic epilepsy, it differs from other forms in that is appears to be progressive only in adolescence, with dramatic worsening of myoclonus and ataxia in the first 6 years after onset. The disease stabilizes in early adulthood, and myoclonus and ataxia may even improve, and there is minimal to no cognitive decline (summary by Ramachandran et al., 2009). (254800)

UniProtKB/Swiss-Prot : 73 Epilepsy, progressive myoclonic 1: An autosomal recessive disorder characterized by severe, stimulus- sensitive myoclonus and tonic-clonic seizures. The onset, occurring between 6 and 13 years of age, is characterized by convulsions. Myoclonus begins 1 to 5 years later. The twitchings occur predominantly in the proximal muscles of the extremities and are bilaterally symmetrical, although asynchronous. At first small, they become late in the clinical course so violent that the victim is thrown to the floor. Mental deterioration and eventually dementia develop.

Wikipedia : 74 Progressive myoclonus epilepsy (PME) is a rare epilepsy syndrome caused by a variety of genetic... more...

Related Diseases for Myoclonic Epilepsy of Unverricht and Lundborg

Diseases related to Myoclonic Epilepsy of Unverricht and Lundborg via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 progressive myoclonus epilepsy 10 33.6 EPM2A CSTB
2 progressive myoclonus epilepsy 1a 31.6 EPM2A CSTB
3 progressive myoclonus epilepsy 6 31.3 GOSR2 EPM2A CSTB
4 myoclonic epilepsy of lafora 31.3 EPM2A CSTB
5 unverricht-lundborg syndrome 31.1 SCARB2 GOSR2 EPM2A CSTB
6 progressive myoclonus epilepsy 4 30.9 SCARB2 EPM2A CSTB
7 early myoclonic encephalopathy 30.2 EPM2A CSTB
8 myoclonus epilepsy 30.1 EPM2A CSTB
9 epilepsy, myoclonic juvenile 29.6 EPM2A CSTB
10 visual epilepsy 29.3 GOSR2 EPM2A
11 epilepsy 29.0 SCARB2 GOSR2 EPM2A CSTB
12 myoclonus 28.8 SCARB2 GOSR2 EPM2A CSTB
13 progressive myoclonus epilepsy 28.6 SCARB2 GOSR2 EPM2A CSTB
14 spinal muscular atrophy with progressive myoclonic epilepsy 13.0
15 progressive myoclonus epilepsy 1b 12.5
16 progressive myoclonic epilepsy with neuroserpin inclusion bodies 12.4
17 epilepsy, progressive myoclonic, 8 12.2
18 epilepsy, progressive myoclonic, 9 12.0
19 spinal muscular atrophy 11.7
20 epilepsy, progressive myoclonic, 1b 11.7
21 epileptic encephalopathy, early infantile, 16 11.7
22 progressive myoclonus epilepsy 7 11.7
23 ceroid lipofuscinosis, neuronal, 4a, autosomal recessive 11.7
24 ceroid lipofuscinosis, neuronal, 6 11.6
25 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 11.6
26 prickle1-related progressive myoclonus epilepsy with ataxia 11.6
27 progressive myoclonus epilepsy 3 11.4
28 progressive myoclonus epilepsy 9 11.4
29 progressive myoclonus epilepsy 8 11.4
30 epilepsy progressive myoclonic type 3 11.4
31 gaucher disease, type iii 11.2
32 encephalopathy, familial, with neuroserpin inclusion bodies 11.2
33 spastic ataxia 5, autosomal recessive 11.2
34 epilepsy, progressive myoclonic, 4, with or without renal failure 11.2
35 epilepsy, progressive myoclonic, 3, with or without intracellular inclusions 11.2
36 epilepsy, progressive myoclonic, 6 11.2
37 epilepsy, progressive myoclonic 7 11.2
38 epilepsy, progressive myoclonic, 10 11.2
39 epilepsy, progressive myoclonic, 11 11.2
40 muscular atrophy 10.6
41 ataxia and polyneuropathy, adult-onset 10.5
42 neuronal ceroid lipofuscinosis 10.5
43 autosomal recessive disease 10.5
44 gaucher's disease 10.4
45 tremor 10.4
46 seizure disorder 10.4
47 motor neuron disease 10.3
48 asah1-related disorders 10.3
49 dentatorubral-pallidoluysian atrophy 10.3
50 ceroid storage disease 10.3

Graphical network of the top 20 diseases related to Myoclonic Epilepsy of Unverricht and Lundborg:



Diseases related to Myoclonic Epilepsy of Unverricht and Lundborg

Symptoms & Phenotypes for Myoclonic Epilepsy of Unverricht and Lundborg

Human phenotypes related to Myoclonic Epilepsy of Unverricht and Lundborg:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 ataxia 31 HP:0001251
2 myoclonus 31 HP:0001336
3 dysarthria 31 HP:0001260
4 mental deterioration 31 HP:0001268
5 bilateral tonic-clonic seizure 31 HP:0002069
6 generalized myoclonic seizure 31 HP:0002123
7 generalized non-motor (absence) seizure 31 HP:0002121

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
ataxia
dysarthria
visual blackouts (stage 1)
eeg - polyspike on photic stimulation (stage 1)
stimulation sensitive segmental myoclonus (stage 2)
more

Clinical features from OMIM:

254800 310370

UMLS symptoms related to Myoclonic Epilepsy of Unverricht and Lundborg:


ataxia, myoclonus

MGI Mouse Phenotypes related to Myoclonic Epilepsy of Unverricht and Lundborg:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 8.92 CSTB EPM2A GOSR2 SCARB2

Drugs & Therapeutics for Myoclonic Epilepsy of Unverricht and Lundborg

Drugs for Myoclonic Epilepsy of Unverricht and Lundborg (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Brivaracetam Approved, Investigational Phase 3 357336-20-0 9837243
2
Zonisamide Approved, Investigational Phase 3 68291-97-4 5734
3 Antibodies Phase 3
4 Rho(D) Immune Globulin Phase 3
5 Immunoglobulins, Intravenous Phase 3
6 Pharmaceutical Solutions Phase 3
7 Immunologic Factors Phase 3
8 gamma-Globulins Phase 3
9 Immunoglobulins Phase 3
10 Anticonvulsants Phase 3
11 Hormones Phase 3
12 Calcium, Dietary Phase 3
13 calcium channel blockers Phase 3
14
Calcium Nutraceutical Phase 3 7440-70-2 271
15
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
16
Ropinirole Approved, Investigational Phase 2 91374-20-8, 91374-21-9 497540 5095
17 Dopamine Agents Phase 2
18 Neurotransmitter Agents Phase 2
19 Dopamine agonists Phase 2
20 Antiparkinson Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Intravenous Immunoglobulin for Unverricht-Lundborg Disease: Single-patient Trial. Unknown status NCT03351569 Phase 3 Intravenous immunoglobulin
2 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease Completed NCT00368251 Phase 3 BRV 2.5 mg;BRV 25 mg;BRV 50 mg
3 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease Completed NCT00357669 Phase 3 Brivaracetam 25 mg;Brivaracetam 50 mg
4 Comparative Study of the Efficiency of Zonisamide in Myoclonus Dystonia: A Monocentric , Randomized in Cross Over and Double Blind Study Versus Placebo Study Completed NCT01806805 Phase 3 zonegran;placebo
5 Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type Unknown status NCT00639119 Phase 2 Ropinirole
6 Clinical, Molecular and Biochemical Characterization of Familial Encephalopathy With Neuroserpin Inclusion Bodies Completed NCT00006176

Search NIH Clinical Center for Myoclonic Epilepsy of Unverricht and Lundborg

Genetic Tests for Myoclonic Epilepsy of Unverricht and Lundborg

Genetic tests related to Myoclonic Epilepsy of Unverricht and Lundborg:

# Genetic test Affiliating Genes
1 Progressive Myoclonic Epilepsy 29
2 Epilepsy, Progressive Myoclonic 1a (unverricht and Lundborg) 29

Anatomical Context for Myoclonic Epilepsy of Unverricht and Lundborg

MalaCards organs/tissues related to Myoclonic Epilepsy of Unverricht and Lundborg:

40
Brain, Skin, Bone, Cortex, Spinal Cord, Thyroid, Globus Pallidus

Publications for Myoclonic Epilepsy of Unverricht and Lundborg

Articles related to Myoclonic Epilepsy of Unverricht and Lundborg:

(show top 50) (show all 343)
# Title Authors PMID Year
1
Unverricht-Lundborg disease in a five-generation Arab family: instability of dodecamer repeats. 6 56
11571333 2001
2
Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. 56 6
9090386 1997
3
Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. 56 6
9054946 1997
4
Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). 6 56
9012407 1997
5
Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1) 56 6
8596935 1996
6
Progressive Myoclonic Epilepsy Type 1 6 61
20301321 2004
7
Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. 61 56
12707458 2003
8
A study of the late form (type Lundborg) of progressive myoclonic epilepsy. 61 56
4194907 1970
9
Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects. 56
20593193 2010
10
Familial cortical myoclonic tremor with epilepsy: the third locus (FCMTE3) maps to 5p. 56
20548044 2010
11
The autosomal recessively inherited progressive myoclonus epilepsies and their genes. 56
19469843 2009
12
Re: Fame 3: a novel form of progressive myoclonus and epilepsy. 56
18166714 2008
13
FAME 3: a novel form of progressive myoclonus and epilepsy. 56
17452583 2007
14
Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. 6
15483648 2005
15
Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. 56
15623692 2004
16
Univerricht-Lundborg disease: underdiagnosed in the Netherlands. 6
15329070 2004
17
N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. 56
12427904 2002
18
Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a few founder mutations. 56
12215838 2002
19
Brainstem involvement in Unverricht-Lundborg disease (EPM1): An MRI and (1)H MRS study. 56
12058102 2002
20
Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. 56
11555622 2001
21
N-acetylcysteine therapy for Unverricht-Lundborg disease. 56
9932979 1999
22
Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. 56
9806543 1998
23
Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient. 6
9342192 1997
24
What is expanded in progressive myoclonus epilepsy? 6
9288090 1997
25
Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. 56
9126745 1997
26
Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. 56
8909441 1996
27
Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan. 6
7543407 1995
28
Sweat gland vacuoles in Unverricht-Lundborg disease: a clue to diagnosis? 56
7991128 1994
29
PME of Unverricht-Lundborg type in the Mediterranean region: linkage and linkage disequilibrium confirm the assignment to the EPM1 locus. 56
8005591 1994
30
Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. 56
8232963 1993
31
Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping. 56
8104628 1993
32
Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora's diseases. 56
1641151 1992
33
Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. 56
1743164 1991
34
Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. 56
1673790 1991
35
Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group. 56
2115761 1990
36
Alpha subunit variants of the human glycine receptor: primary structures, functional expression and chromosomal localization of the corresponding genes. 56
2155780 1990
37
Deficit of spinal cord glycine/strychnine receptors in inherited myoclonus of Poll Hereford calves. 56
2845573 1988
38
"Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. 56
6137660 1983
39
Assignment of LH XVI to chromosome 3 in the mouse. 56
6160178 1980
40
Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. 56
109240 1979
41
[On genetics of progressive myoclonic epilepsies (Unverricht-Lundborg)]. 56
5868699 1965
42
Familial myoclonic epilepsy and its association with cerebellar disturbance. 56
13729348 1960
43
Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis. 56
13269595 1955
44
Familial degeneration of the cerebral gray matter in childhood with convulsions, myoclonus, spasticity, cerebellar ataxia, choreoathetosis, dementia, and death in status epilepticus; differentiation of infantile and juvenile types. 56
14851183 1951
45
Hereditary myoclonus epilepsy; two cases with pathological findings. 56
18128978 1949
46
Discovering candidate imprinted genes and imprinting control regions in the human genome. 61
32475352 2020
47
ASAH1 pathogenic variants associated with acid ceramidase deficiency (ACD): Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). 61
32449975 2020
48
Focus on progressive myoclonic epilepsy in Berardinelli-Seip syndrome. 61
32440981 2020
49
Drug Treatment of Progressive Myoclonic Epilepsy. 61
31939107 2020
50
De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy. 61
32169168 2020

Variations for Myoclonic Epilepsy of Unverricht and Lundborg

ClinVar genetic disease variations for Myoclonic Epilepsy of Unverricht and Lundborg:

6 (show top 50) (show all 503) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EPM2A NC_000006.12:g.(?_145686102)_(145686316_?)deldeletion Pathogenic 462911 6:145686102-145686316
2 GOSR2 NM_004287.5(GOSR2):c.184A>T (p.Lys62Ter)SNV Pathogenic 659698 17:45008554-45008554 17:46931188-46931188
3 CSTB NM_000100.3(CSTB):c.64C>T (p.Gln22Ter)SNV Pathogenic 575156 rs1569006250 21:45196087-45196087 21:43776206-43776206
4 CSTB NM_000100.3(CSTB):c.200_203dup (p.Val69fs)duplication Pathogenic 659184 21:45194176-45194177 21:43774295-43774296
5 EPM2A NC_000006.12:g.(?_145625675)_(145735518_?)deldeletion Pathogenic 654665 6:145946811-146056654 6:145625675-145735518
6 EPM2A NC_000006.12:g.(?_145625675)_(145635506_?)deldeletion Pathogenic 830902 6:145946811-145956642
7 GOSR2 NC_000017.11:g.(?_46923173)_(46940633_?)deldeletion Pathogenic 831185 17:45000539-45017999
8 CSTB NC_000021.8:g.(?_44838120)_(45629566_?)deldeletion Pathogenic 830406 21:44838120-45629566
9 EPM2A NM_005670.4(EPM2A):c.835G>T (p.Gly279Cys)SNV Pathogenic 834981 6:145948713-145948713 6:145627577-145627577
10 GOSR2 NM_004287.5(GOSR2):c.262del (p.Gln88fs)deletion Pathogenic 859319 17:45009490-45009490 17:46932124-46932124
11 EPM2A NM_005670.4(EPM2A):c.74C>A (p.Ser25Ter)SNV Pathogenic 862225 6:146056561-146056561 6:145735425-145735425
12 EPM2A NM_005670.4(EPM2A):c.721C>T (p.Arg241Ter)SNV Pathogenic 3098 rs104893950 6:145948827-145948827 6:145627691-145627691
13 CSTB NM_000100.3(CSTB):c.202C>T (p.Arg68Ter)SNV Pathogenic 8396 rs74315442 21:45194178-45194178 21:43774297-43774297
14 CSTB NM_000100.3(CSTB):c.10G>C (p.Gly4Arg)SNV Pathogenic 8397 rs74315443 21:45196141-45196141 21:43776260-43776260
15 CSTB NM_000100.3(CSTB):c.-210CCCCGCCCCGCG(2_3)NT expansion Pathogenic 8398 21:45196360-45196371 21:43776479-43776490
16 CSTB CSTB, 2-BP DEL, 2404TCdeletion Pathogenic 8399
17 CSTB NM_000100.3(CSTB):c.212A>C (p.Gln71Pro)SNV Pathogenic 8400 rs121909346 21:45194168-45194168 21:43774287-43774287
18 GOSR2 NM_004287.5(GOSR2):c.430G>T (p.Gly144Trp)SNV Pathogenic 30406 rs387906881 17:45012488-45012488 17:46935122-46935122
19 CSTB NM_000100.3(CSTB):c.-210_-199(30_125)NT expansion Pathogenic 55956 21:45196349-45196360 21:43776468-43776479
20 CSTB NM_000100.4(CSTB):c.168+2_168+21delinsAAindel Pathogenic 161421 rs864309482 21:45194518-45194537 21:43774637-43774656
21 CSTB NM_000100.3(CSTB):c.168+2_168+19deldeletion Pathogenic 161420 rs312262707 21:45194520-45194537 21:43774639-43774656
22 CSTB NM_000100.3(CSTB):c.149G>A (p.Gly50Glu)SNV Pathogenic 161419 rs312262708 21:45194558-45194558 21:43774677-43774677
23 CSTB NM_000100.3(CSTB):c.136C>T (p.Gln46Ter)SNV Pathogenic 161418 rs545986367 21:45194571-45194571 21:43774690-43774690
24 CSTB NM_000100.3(CSTB):c.67-1G>CSNV Pathogenic/Likely pathogenic 8395 rs147484110 21:45194641-45194641 21:43774760-43774760
25 CSTB NM_000100.3(CSTB):c.125C>A (p.Ser42Ter)SNV Pathogenic/Likely pathogenic 55957 rs386833439 21:45194582-45194582 21:43774701-43774701
26 CSTB NM_000100.3(CSTB):c.168G>A (p.Lys56=)SNV Pathogenic/Likely pathogenic 55958 rs386833440 21:45194539-45194539 21:43774658-43774658
27 CSTB NM_000100.3(CSTB):c.169-2A>GSNV Pathogenic/Likely pathogenic 55959 rs386833441 21:45194213-45194213 21:43774332-43774332
28 CSTB NM_000100.4(CSTB):c.214_215TC[2] (p.Leu73fs)short repeat Pathogenic/Likely pathogenic 55960 rs796943858 21:45194161-45194162 21:43774280-43774281
29 CSTB NM_000100.3(CSTB):c.66G>A (p.Gln22=)SNV Pathogenic/Likely pathogenic 55961 rs386833443 21:45196085-45196085 21:43776204-43776204
30 SCARB2 NM_005506.4(SCARB2):c.361C>T (p.Arg121Ter)SNV Pathogenic/Likely pathogenic 206709 rs200053119 4:77102169-77102169 4:76181016-76181016
31 GOSR2 NM_004287.4(GOSR2):c.336+1G>ASNV Pathogenic/Likely pathogenic 211092 rs141554661 17:45009566-45009566 17:46932200-46932200
32 EPM2A NM_005670.4(EPM2A):c.495G>A (p.Trp165Ter)SNV Pathogenic/Likely pathogenic 381553 rs781291421 6:145956604-145956604 6:145635468-145635468
33 EPM2A NM_005670.4(EPM2A):c.560C>T (p.Thr187Ile)SNV Likely pathogenic 802281 6:145956539-145956539 6:145635403-145635403
34 GOSR2 NM_004287.4(GOSR2):c.337-2A>GSNV Likely pathogenic 578675 rs1568177307 17:45012393-45012393 17:46935027-46935027
35 CSTB NM_000100.3(CSTB):c.10G>T (p.Gly4Trp)SNV Likely pathogenic 431700 rs74315443 21:45196141-45196141 21:43776260-43776260
36 PRICKLE2 NM_198859.4(PRICKLE2):c.1314G>C (p.Gln438His)SNV Conflicting interpretations of pathogenicity 433101 rs202170644 3:64132852-64132852 3:64147176-64147176
37 PRICKLE2 NM_198859.4(PRICKLE2):c.594C>T (p.Cys198=)SNV Conflicting interpretations of pathogenicity 448123 rs367680077 3:64142844-64142844 3:64157168-64157168
38 SCARB2 NM_005506.4(SCARB2):c.430A>T (p.Ile144Leu)SNV Conflicting interpretations of pathogenicity 449287 rs117600063 4:77100852-77100852 4:76179699-76179699
39 PRICKLE2 NM_198859.4(PRICKLE2):c.1602G>A (p.Thr534=)SNV Conflicting interpretations of pathogenicity 478004 rs144757200 3:64132564-64132564 3:64146888-64146888
40 CSTB NM_000100.3(CSTB):c.1_2insAT (p.Met1fs)insertion Conflicting interpretations of pathogenicity 423466 rs1044894207 21:45196149-45196150 21:43776268-43776269
41 GOSR2 NM_004287.5(GOSR2):c.94+7A>CSNV Conflicting interpretations of pathogenicity 695955 17:45006957-45006957 17:46929591-46929591
42 SCARB2 NM_005506.4(SCARB2):c.9A>G (p.Arg3=)SNV Conflicting interpretations of pathogenicity 507452 rs148558907 4:77134688-77134688 4:76213535-76213535
43 CSTB NM_000100.3(CSTB):c.-12G>ASNV Conflicting interpretations of pathogenicity 510088 rs779920568 21:45196162-45196162 21:43776281-43776281
44 EPM2A NM_005670.4(EPM2A):c.24G>A (p.Val8=)SNV Conflicting interpretations of pathogenicity 137222 rs587780938 6:146056611-146056611 6:145735475-145735475
45 EPM2A NM_005670.4(EPM2A):c.129C>G (p.Ala43=)SNV Conflicting interpretations of pathogenicity 137223 rs547147183 6:146056506-146056506 6:145735370-145735370
46 GOSR2 NM_004287.4(GOSR2):c.29+8C>TSNV Conflicting interpretations of pathogenicity 137489 rs573306680 17:45000595-45000595 17:46923229-46923229
47 EPM2A NM_005670.4(EPM2A):c.376A>G (p.Ile126Val)SNV Conflicting interpretations of pathogenicity 167038 rs150452237 6:146007358-146007358 6:145686222-145686222
48 SCARB2 NM_005506.4(SCARB2):c.382C>G (p.Pro128Ala)SNV Conflicting interpretations of pathogenicity 196412 rs143558324 4:77102148-77102148 4:76180995-76180995
49 EPM2A NM_005670.4(EPM2A):c.680C>T (p.Ala227Val)SNV Conflicting interpretations of pathogenicity 196413 rs147399860 6:145956419-145956419 6:145635283-145635283
50 CSTB NM_000100.3(CSTB):c.121G>A (p.Val41Met)SNV Conflicting interpretations of pathogenicity 195015 rs143153487 21:45194586-45194586 21:43774705-43774705

UniProtKB/Swiss-Prot genetic disease variations for Myoclonic Epilepsy of Unverricht and Lundborg:

73
# Symbol AA change Variation ID SNP ID
1 CSTB p.Gly4Arg VAR_002206 rs74315443

Expression for Myoclonic Epilepsy of Unverricht and Lundborg

Search GEO for disease gene expression data for Myoclonic Epilepsy of Unverricht and Lundborg.

Pathways for Myoclonic Epilepsy of Unverricht and Lundborg

GO Terms for Myoclonic Epilepsy of Unverricht and Lundborg

Cellular components related to Myoclonic Epilepsy of Unverricht and Lundborg according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.13 SCARB2 GOSR2 EPM2A
2 late endosome membrane GO:0031902 8.62 SCARB2 GOSR2

Sources for Myoclonic Epilepsy of Unverricht and Lundborg

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....